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Introduction 
The macula is a specialised part of the central retina 
which is responsible for optimal spatial and colour vision. 
Age-related macular degeneration (AMD) is the leading cause 
of blind registration in the western world (Bressler 2004). 
Epidemiological studies carried out in different countries 
have been remarkably consistent in demonstrating that 
the prevalence of eye disease, and associated vision loss, is 
critically age-dependent (Bunce & Wormald 2008; Kelliher 
et al. 2006). Indeed, for each decade over the age of 40 years, 
the amount of blindness and vision loss increases threefold. 
Interestingly, in developed countries, 48% of all cases of blind 
registration in persons aged 40 years and over are attributable 
to AMD. AMD is seen in about 2% of the 70–80-year-old 
age group, 4% in the 81–84-year-old age group and 13% in 
those aged 85 years and older. It has been estimated that 
there are currently 80 000 people in the Republic of Ireland 
(http://www.fightingblindness.ie/) and 417 000 people in the 
UK (Owen et al. 2003) suffering with AMD and these figures are 
expected to double by 2020. In fact, the most recent analysis 
of the blindness register in the Republic of Ireland revealed that 
the number of persons registered blind as a consequence of 
AMD more than doubled (113% increase) in the short period 
from 1996 to 2003 (Kelliher et al. 2006). A similar increasing 
trend has also been noted in the UK, where AMD was observed 
to account for 29% of blindness registrations in 1980, but 
increased to 52% by 1997 (Bamashmus et al. 2004). Given our 
ever-increasing life expectancy, these upward trends in AMD 
prevalence and associated blindness are certain to continue, 
and will cement AMD’s position as the most significant 
sight-threatening condition likely to affect the growing, and 
ageing, population in the UK and Ireland.
The impact of vision loss, secondary to AMD, manifests as 
reduced ability to drive, to read, to recognise faces or to 
perform routine daily visual tasks. There is also a consequential 
loss of social independence, which is increasingly problematic 
in an era of declining family support and lengthening periods 
of retirement. When asked what health condition they fear 
most, one-third of people will identify blindness, another third 
will identify cancer and the final third will identify a wide range 
of ailments or fears. Most people, however, regard it as unlikely 
that they will ever develop blindness or visual impairment. 
Indeed, health policy-makers often regard vision loss as being of 
relatively minor importance or priority. It is worth emphasising 
that even small degrees of visual impairment have important 
adverse impacts on both the quality and length of life. For 
example, vision of 6/12 or less is associated with the following: 
loss of driving licence; increased risk of falls, hip fractures and 
depression; loss of social independence; admission to a nursing 
home 4 years before their counterparts with normal vision; 
and perhaps most importantly, a reduced ability to enjoy 
healthy and independent ageing. Such consequences of vision 
loss are not only costly to the individual in personal terms, 
they also have significant direct and indirect financial cost 
implications to the exchequer – costs that continue to escalate.
The aetiology of AMD is poorly understood, yet there 
is consensus that genetic background and certain 
environmental/lifestyle risk factors (eg smoking) and their 
interaction predispose an individual to the condition (Schork 
1997). Current treatment interventions, such as anti-vascular 
endothelial growth factor agents, have resulted in better 
outcomes for patients with neovascular AMD (Bressler et 
al. 2010; Brown et al. 2009; Rosenfeld et al. 2006). These, 
however, are costly and cumbersome to the healthcare provider 
and patient. In addition, there is no effective treatment for 
the atrophic (dry) form of late AMD, which has a similarly 
detrimental effect on a patient’s quality of life. 
The dietary carotenoids lutein (L), zeaxanthin (Z), and 
meso-zeaxanthin (meso-Z) accumulate at the macula where 
they are collectively known as macular pigment (MP) and give 
the macula its yellow appearance. L and Z can be obtained 
from many foods (Sommerburg et al. 1998), whereas meso-Z 
is not present in a conventional western diet, although it can 
be found in certain types of seafood (Maoka et al. 1986). 
MP has generated interest in recent years because of its 
possible protective role in AMD, putatively attributable to its 
antioxidant properties and/or its prereceptoral filtration of 
damaging short-wavelength (blue) light (Beatty et al. 2000a; 
Tomany et al. 2004). 
In summary, AMD, which is already at epidemic levels, will 
continue to increase in prevalence with the ageing and 
growing population. AMD destroys central vision and impairs 
quality of life in the elderly. Current treatment options, while 
effective in some patients, are costly and present a massive 
and increasing financial challenge for healthcare services 
Optometry in Practice 2011   Volume 12   Issue 4   135 – 144
Date of acceptance: 31 August 2011. Address for correspondence: Dr John Nolan, Macular Pigment Research Group, Chemical and Life Sciences, 
Waterford Institute of Technology, Cork Road, Waterford, Ireland. jmnolan@wit.ie.
C-17733 2 CET points for optometrists and therapeutics 
© 2011 The College of Optometrists
Online AMD research study for optometrists:  
current practice in the Republic of Ireland and UK
James Loughman,1,2 John M Nolan,3 James Stack3 and Stephen Beatty3 
1Optometry Department, Dublin Institute of Technology, Dublin, Ireland
2African Vision Research Institute, University of KwaZulu Natal, Durban, South Africa. 3Waterford Institute of Technology, Waterford, Ireland
J Loughman et al.
136
Results and discussion
The 11 questions posed to optometrists as part of this online 
research study are presented in Table 1.
The majority of practices (81%) reported patient numbers of 
5000 per year or less. The reported percentage of patients 
presenting with AMD ranged from 0 to 90% (Figure 1). The 
mean ± standard deviation (SD) percentage of patients 
presenting with AMD was 10.8 ± 10.8. However, some practices 
reported much higher percentages presenting with AMD. For 
example, of the 724 practice respondents, 65 reported AMD 
prevalence in excess of 20% among practice attendees. 
The Amsler grid was the most widely reported technique used 
routinely to check for the presence of AMD (35%). The range 
of additional techniques employed to detect the presence of 
AMD can be seen in Figure 2.
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Figure 2. Reported routine age-related macular 
degeneration (AMD) and AMD risk assessment techniques.
worldwide. There is a clear need, therefore, for attention to be 
directed towards the prevention of AMD and its progression. 
The optometrist, who represents the first line of eye care, is 
uniquely placed to implement such a prevention strategy for 
AMD. However, it appears that current ophthalmic practice 
for AMD assessment and prevention may be failing to 
exploit the latest technological developments and scientific 
knowledge. It is not clear what methods, if any, are being used 
to identify patients at risk of AMD, or what preventive methods, 
if any, are being utilised to help reduce risk of AMD and its 
progression. This investigator-driven, online AMD research 
study was designed to address these precise questions for a 
target population consisting of optometrists in the Republic of 
Ireland and the UK.
Methods 
The Institute of Vision Research (IVR), based in Waterford, 
Ireland, initiated and designed the current research study. The 
survey questions asked as part of this online AMD research 
study (all presented below in the Results section of this report) 
were prepared by members of the IVR with expertise and input 
from the following disciplines: ophthalmology, optometry, 
vision science, nutrition and statistics. 
The Association of Optometrists in Ireland and the 
College of Optometrists in the UK were informed of the study 
and its objectives, and agreed to contact (by email) their 
members and invite them to participate in the online AMD 
survey. Seven hundred and fifty emails were circulated in 
Ireland and 8049 emails were circulated in the UK. Reminder 
emails were sent to Association and College members after 
6 weeks. The survey was open to members for a total of 
3 months. In total, 724 respondents (8.2%) completed and 
submitted the survey online.
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Figure 1. Reported percentage of patients presenting with signs of age-related macular degeneration (AMD).
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Table 1. Online questionnaire items
Question no. Question 
1 What is your average annual  
patient number?
2 Approximately what percentage of 
your patients present signs of AMD?
3 What assessments do you routinely 
perform to check for the presence of 
AMD and/or risk of developing AMD?
4 If you measure macular pigment, 
which device do you use?
5 Do you currently recommend eye 
supplements for patients with AMD?
6 Do you currently recommend eye 
supplements for patients at risk of 
developing AMD?
7 Which supplements do you 
recommend for AMD?
8 What is your main reason for not 
recommending supplements?
9 What factors influence your decision 
to recommend eye supplements,  
if any?
10 Within the last 12 months, 
approximately how many patients 
have you recommended eye 
supplements to?
11 Within the last 12 months, 
approximately how many patients 
have you noticed, or the patients 
themselves have reported, an 
improvement in their AMD following 
recommendation of the eye 
nutritional supplement?
Although 16% of respondents to question 3 indicated 
that measurement of MP comprised part of their routine 
investigations for AMD, only 3.7% (27 practices) named the 
MP measurement device they used in response to question 4. 
Of these, 13 use the Macuscope device, 13 use the Mpod, and 
one uses the Zeiss Visucam 200. In addition, one respondent 
reported measuring MP using an ophthalmoscope, and one 
respondent reported using a Friedmann analyser; however, 
these devices are not suited to measure MP. 
A significant majority of practices (90.6%) are currently 
recommending eye supplements for patients with 
established AMD. In addition, 73.2% of respondents indicated 
that they are currently recommending eye supplements 
for patients at risk of AMD. ICaps (382 practices, 52.8%) 
and Macushield (351 practices, 48.5%) are the most 
recommended supplements for AMD (Figure 3). In those 
practices recommending only a single supplement, ICaps and 
Macushield again predominate (Figure 4).
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Figure 3. Supplements recommended in optometry 
practices for age-related macular degeneration. Note that 
many practices recommend more than one supplement, 
and therefore the cumulative counts add up to more than 
the total number of survey respondents. 
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Figure 4. Supplement recommendations in practices 
recommending a single supplement.
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Strong scientific evidence was cited as the principal reason 
supporting the recommendation of supplements for AMD 
(Figure 5). 
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Figure 5. Reasons cited for recommending supplements for 
age-related macular degeneration.
In the small number of practices (9.4%) not currently 
recommending such supplements, the reasons for not 
recommending them were more evenly dispersed, although 
interestingly, lack of scientific evidence was the most common 
reason given (Figure 6).
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Figure 6. Reasons cited by practices not recommending 
supplements for age-related macular degeneration.
Presence of clinical signs of the atrophic form of late AMD 
(including vision loss) was the strongest influencing factor 
involved in clinical decisions to recommend AMD supplements 
to a patient. This was closely followed by the presence of 
early AMD, including signs such as drusen and/or pigmentary 
changes at the macula, but without significant vision loss. 
Increased risk of developing AMD was the least commonly 
cited reason for prescribing supplements (Figure 7).
 
0
100
200
300
400
500
Patients with 
advanced AMD 
with affected vision 
(dry type)
Patients with early 
AMD with no 
affected vision 
(i.e. drusen; 
pigmentary 
changes)
Patients with early 
AMD with affected 
vision (wet type)
Patients at known 
risk of developing 
AMD with no 
affected vision 
(e.g. family history, 
cigarette smoker)
N
um
be
r o
f p
ra
ct
ic
es
Figure 7. Reasons for prescribing eye supplements. AMD, 
age-related macular degeneration.
For the majority of practices, supplements were recommended 
for fewer than 50 patients in the preceding 12 months, 
while only a small minority of respondents estimated a 
recommendation rate greater than 200 (Figure 8). 
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Figure 8. Estimated number of patients to whom eye 
supplements were recommended in the preceding 
12-month period.
In total, 22% (158) of practices reported some form of 
improvement in at least one of their AMD patients following 
supplementation (Figure 9). For these practices, patient 
improvement was noted, on average, in 9% (±11%) of 
patients to whom supplements had been recommended. 
For the majority of cases, it was not possible to assign these 
improvements to any one particular supplement. This was 
possible, however, for the 265 practices, identified through 
the survey, that recommend a single supplement, thereby 
enabling a determination of the relative efficacy of individual 
supplement types. 
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Figure 9. Estimated percentage of patients showing 
improvement in age-related macular degeneration following 
supplementation. *Statistical outliers.
The differences in reported improvement across supplement 
types are presented in Table 2. Treating reported improvement 
as a simple binary variable (ie yes/no improvement response), 
Pearson chi-squared analysis reveals a statistically significant 
difference between the relative improvement between 
supplements (Pearson chi-squared test, P = 0.008). Of note, 
in Table 2 the reported improvement is highest amongst those 
practices using Macushield (the only supplement containing 
meso-Z: see below for discussion on this interesting finding). 
Further statistical analysis of the actual reported percentage 
improvement for each practice also reveals a significant 
difference between supplement types (Kruskal–Wallis test, 
P = 0.031). Once again, the percentage improvement is highest 
in those practices that recommend Macushield exclusively. 
These findings are illustrated in Figure 9. 
Table 2. Improvement in age-related macular 
degeneration reported for supplements
Improvement noticed
Supplement No Yes Total
ICaps 66 46 112
Macushield 42 68 110
Ocuvite Lutein 6 6 12
Ocuvite Preservision 5 5 10
Other 15 6 21
Discussion
This online AMD research study was uniquely designed to 
investigate current practice for AMD assessment, therapeutic 
and prevention strategies amongst the optometric 
communities in the Republic of Ireland and the UK. While the 
number of respondents (n = 724) and response rate (5.27%) 
are typical of modern online surveys, and remain sufficient 
for reliable statistical interpretation of the results contained 
herein, it should be recognised that the responses described 
may not be wholly reflective of optometric practice across 
the UK and Ireland. It should also be recognised that some 
inconsistencies and irregularities in response have been 
noted, including the number of practices reporting that they 
measure MP versus the number of respondents who named 
the MP device routinely used. Also, the responses to question 
3 remain somewhat puzzling, with only a minority of 
respondents indicating the use of fundus evaluation 
(ophthalmoscopy, Volk biomicroscopy or fundus photography) 
to assess for the presence of signs of AMD. 
Interestingly, the average number of patients presenting 
with signs of AMD was indicated to be around 10%. 
Importantly, as the question about the number of patients 
per annum included all patients, of all ages, a figure of 10% 
appears somewhat high, but is consistent with the increasing 
prevalence of AMD in the ageing population, and also with 
the likely age profile of patients attending optometry practice, 
which would tend to be skewed to older age. Also, and of 
interest, a large number of practices reported an extremely 
high number of people presenting with signs of AMD. This 
finding is most likely explained by a particularly older age 
patient profile in these particular practices. This survey did not 
differentiate the type of practice worked in by the respondents, 
and it should be recognised that this could influence the 
high estimated AMD prevalence reported here (for example, 
if a high percentage of hospital eye service optometrists 
responded to the survey).
When asked what assessments they routinely perform to check 
for the presence of AMD and/or risk of their patients developing 
this condition, it was interesting to note that the Amsler grid 
was the most commonly reported technique to be used 
(35%). The low response rate for ophthalmoscopy (14%), Volk 
examination (8%) or fundus photography (16%) would seem 
highly surprising, especially given that it is expected that at 
least one of these techniques would be used during the course 
of every optometric eye examination, particularly among those 
patients at risk of developing AMD. While it is encouraging to 
see newer technologies such as optical coherence tomography 
(OCT) in use, such techniques could not yet be regarded as 
routine for optometric practice. Of more concern, however, 
are the low numbers of practitioners (7%) who report that 
they routinely perform an AMD risk assessment. Given the 
nature of the condition, and the treatment options available, it 
appears sensible that efforts should be made to detect risk of 
this condition before the disease is allowed to manifest.
MP, made up of the dietary carotenoids L, Z and meso-Z, is now 
believed to play an important role in eye health, particularly 
for AMD. Indeed, the protective role of this pigment lies in 
its ability to function as a powerful antioxidant (Beatty et al. 
2000b) and as a prereceptoral filter of potentially damaging, 
short-wavelength blue light (Haegerstrom-Portnoy 1988). It 
is now accepted that free radical damage caused by oxidative 
stress, which is exacerbated by irradiation of the retina with 
blue light, is aetiologically important in AMD. It makes sense, 
therefore, that an individual’s MP is key to reducing these 
stresses that ultimately lead to AMD (Loane et al. 2008). 
It is interesting to note that only a very small percentage of 
practices (3.7%) currently have the capacity to measure this 
important dietary pigment for people with, or at risk of, AMD. 
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Given that this pigment is modifiable by dietary refinement 
and/or supplementation with the macular carotenoids, and 
given that enrichment of this pigment is believed to confer 
protection against AMD, optometrists are now advised to 
recommend dietary supplements to patients with, or at risk 
of, AMD. However, it is important that the eye care specialist 
endeavours to identify response to such dietary modification 
or supplementation, which can only be achieved by measuring 
this pigment in vivo. This is important as it is also known that 
not all individuals respond to supplementation. There are many 
different supplements available, containing many different 
formulations and concentrations of the macular carotenoids. 
Poor or slow response to one supplement might warrant 
change in recommendation to an alternative supplement.
We believe that the reason for such a small number of eye care 
specialists in the Republic of Ireland and the UK measuring this 
pigment is due to the technology that has been available up 
to now. Indeed, the current accepted gold standard within the 
scientific community for measuring MP is a technique known 
as heterochromatic flicker photometry (HFP). It is our view that 
this subjective technique, which requires customisation of the 
method and training for the patients, has only been suitable 
for scientific studies (given the length of time required to 
customise the stimulus and train the patient – circa 20 minutes 
per patient). Commercial organisations have tried to promote 
‘clinical’ versions of this flicker technique for the optometrist; 
however, this has not been successful, as confirmed by the 
current survey results showing the very small number of 
practices actually using their techniques. For example, the 
Macuscope uses a type of HFP to measure MP, but fails to allow 
for customisation of the method. This, in our opinion, results 
in a far too difficult and unreliable measurement. Another 
instrument, the M-POD, which again uses a type of HFP to 
measure MP, has significantly improved the measurement 
technique. It can, however, occasionally prove difficult for 
some patients, and tends to yield lower results compared to 
the gold-standard device. A new device, known as the clinical 
densitometer, appears to have successfully addressed most of 
the earlier problems with the measurement of MP in clinical 
practice, and produces reliable and reproducible results that, in 
our opinion, have the potential to bring value to the optometry 
community and its patient base. Importantly, using these 
newer technologies, this measurement now takes only a few 
minutes to perform and the data obtained are reliable, making 
it suitable for the clinical setting.
It was no surprise to see that over 90% of practices currently 
recommend some form of nutritional eye supplement. 
Interestingly, when asked if they recommend supplements 
for patients at risk of AMD (ie currently not presenting with 
disease but believed to be at risk due to a positive family 
history or other combined risk profile), it was encouraging to 
see a high percentage of practices (n > 70%) making such a 
recommendation. This recommendation is consistent with 
the scientific view that risk reduction for AMD, which includes 
retinal enrichment with the macular carotenoids, needs to be 
established before the disease is allowed to develop to achieve 
maximum effect. Indeed, given that AMD is the result of 
cumulative and chronic damage caused by free radicals over a 
person’s lifetime, it makes sense that preventive methods are 
implemented during this same time period. 
Given the estimated percentage of patients with AMD 
attending for optometric examination (10.8%), it is perhaps 
surprising to note the relatively low rates of recommendation 
of nutritional supplements. For the majority of practices, 
the estimated number of recommendations is less than one 
per week, with very few practices reporting more than four 
recommendations per week. Given the prevalence of AMD, the 
likely age profile of patients attending optometry practices, 
and the prevalence of confirmed risk factors for AMD such as 
smoking, this likely represents a significant underexploitation 
of nutritional supplementation for AMD and AMD risk.
In response to the question as to what actual type (brand) 
of supplement was recommended, the results clearly show 
that ICaps (containing 10mg L/Z plus antioxidants) and 
Macushield (containing 10mg L, 10 mg meso-Z and 2 mg Z) are 
the two leading choices amongst the optometry communities 
in the Republic of Ireland and the UK. Of the 724 respondents, 
382 recommend ICaps and 351 recommend Macushield, and 
these remain the most commonly recommended supplements 
regardless of whether practices stock just one or more than 
one supplement.
When queried on the reasons for recommending their chosen 
eye supplement over others, ‘strong scientific evidence’ 
was the main reported reason for supplement choice. It 
appears, therefore, that the optometry community in the 
Republic of Ireland and the UK feels that the supplements 
they recommend (ie mainly ICaps and Macushield) have the 
most scientific support to justify such recommendations. 
However, it is important to point out that, for the leading 
recommended supplement, ICaps, this is not the case. This 
point is supported by the fact that, to our knowledge, there is 
not a single published scientific study in the literature that has 
commented on response, safety and/or suitability of the ICaps 
supplement for patients with or at risk of AMD. In contrast, 
however, the Ocuvite Lutein supplement has, indeed, many 
supporting published studies commenting on the suitability of 
this supplement for patients with or at risk of AMD (Loughman 
et al. 2010; Nolan et al. 2011; Trieschmann et al. 2007). The 
second most recommended supplement, Macushield, also 
has a growing body of scientific evidence in support of this 
particular supplement for patients with or at risk of AMD 
(Bone et al. 2007; Connolly et al. 2010). 
There are many different types of L available (eg free versus 
ester), in different formulations and concentrations, which 
may influence how the patient responds to the supplement. 
It is important, therefore, that the optometrist is informed 
of these facts, and understands that patients’ response to 
supplements is not consistent across the many supplements 
available. In summary, therefore, the optometrist is advised 
to seek appropriate scientific data (eg from clinical trials) 
providing information on response, safety of consumption 
and efficacy for AMD when deciding on which supplement to 
recommend to patients.
The final objective of this research survey was to try and 
identify whether signs and symptoms of AMD were improved 
in patients using supplements recommended by the practice 
(optometrist). Although this aspect required respondents 
to make a subjective analysis of their clinical experience of 
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supplementation (question 11), robust statistical analysis 
confirmed that there was a statistically significant difference 
with respect to the reported efficacy of supplements, which 
was dependent on the actual supplement recommended, and 
was in favour of Macushield. This finding, albeit provocative, 
is important given that Macushield is the only commercially 
available supplement that contains all three of the macular 
carotenoids, including the central carotenoid, meso-Z. Indeed, 
the view of these clinical optometrists is consistent with 
recently published scientific studies which confirm significant 
enrichment of MP in individuals following supplementation with 
this particular carotenoid supplement (Connolly et al. 2010). 
It is also consistent with a recently published study confirming 
the enhanced antioxidant capacity of the carotenoids when 
all three are present in formulation (as opposed to any of 
the individual carotenoids at the same concentration) 
(Li et al. 2010). 
This online AMD research survey has provided valuable 
information as to current practice amongst Irish and UK 
optometrists for AMD. It is clear from this survey that AMD 
continues to present a challenge to the optometry community. 
Current methods to assess and manage risk of AMD are 
improving; however, the optometrist is advised to consider 
advanced technologies such as OCT, and in particular, to 
consider incorporating the measurement of MP into routine 
optometric practice. This should form part of an overall formal 
AMD risk assessment strategy, aimed at identifying those 
patients at highest risk of developing AMD (such as those with 
low MP, family history of AMD and smokers) and suffering 
the associated visual losses and lifestyle effects of such visual 
impairment within their lifetime. Research in the area of 
AMD prevention, particularly around nutrition and macular 
carotenoids, is ongoing and supports (albeit inconclusively 
as of yet) the role of the macular carotenoids for AMD and 
for the ‘at-risk’ patient. When making recommendations on 
nutritional supplements, the optometrist should base such 
recommendations on supporting and available scientific 
studies on carotenoids/antioxidants and AMD. It is our view 
that the scientific literature is in favour of a supplement that 
contains all three macular carotenoids. 
It is encouraging to see the optometry community reporting 
many cases of improved AMD (albeit crudely assessed and 
reported) following recommendation of nutritional eye 
supplements. However, further work is required to understand 
such benefits fully, in order to try to identify the type of 
patient who could benefit most from such recommendations. 
There are now several clinical trials underway investigating the 
potential of nutritional supplementation for AMD, including 
a major European-funded study about to commence in 
Waterford, Ireland. These studies have the capacity to address 
the outstanding issues more completely and provide more 
definitive information on the role of MP supplements in AMD. 
In conclusion, the optometrist who represents a very important 
first line of eye care is advised to review the scientific literature 
on this ever-growing topic regularly. Indeed, it is important 
that the totality of the available evidence is examined, which, 
for now, suggests a positive role for the macular carotenoids, 
L, Z and meso-Z for patients at risk of, or presenting with, AMD. 
 Summary
Age-related macular degeneration (AMD) is the leading 
cause of blind registration in the western world, and 
the number of people with this condition continues to 
rise due to the ageing population. AMD destroys central 
vision and impairs quality of life in the elderly. Current 
treatment options, while effective in some patients, 
are costly and present a massive financial challenge 
for Europe and its healthcare services. There is a clear 
need, therefore, for attention to be directed towards 
the prevention or delay of AMD and its progression. The 
optometrist, who represents the first line of eye care, 
is uniquely placed to implement such a prevention 
strategy for AMD.
This paper reports and discusses findings from an online 
AMD research survey, designed to investigate current 
practice for AMD amongst optometric practitioners in 
the Republic of Ireland and the UK. 
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Multiple choice questions
This paper is reference C-17733. Two points are available 
for optometrists and therapeutics. Please use the inserted 
answer sheet. Copies can be obtained from Optometry in 
Practice Administration, PO Box 6, Skelmersdale, Lancashire 
WN8 9FW. There is only one correct answer for each question.
1. For each decade over the age of 40 how much does the 
amount of blindness and visual loss increase?
(a) Twofold
(b) Threefold
(c) Fourfold
(d) Fivefold
2. Vision of 6/12 or less is associated with which of 
the following:
(a) Increased risk of falls
(b) Depression
(c) Loss of social independence
(d) All of the above
3. Regarding macular carotenoids, which of the following 
statements is incorrect?
(a) Macular pigment consists of three dietary carotenoids
(b) Meso-zeaxanthin is present in a conventional western diet
(c) Lutein can be obtained from many foods
(d) Macular pigment can filter blue light
4. Which of these techniques was most often employed to 
check for the presence of AMD?
(a) Ophthalmoscopy
(b) Retinal photography
(c) Amsler grid
(d) Measurement of macular pigment
5. What percentage of respondents are currently 
recommending eye supplements for patients at risk 
of AMD?
(a) 90.6%
(b) 73.2%
(c) 52.8%
(d) 48.5%
6. Which of the following was the strongest influence 
when deciding whether to recommend eye supplements to 
a patient?
(a) Presence of drusen
(b) Presence of pigmentary changes
(c) Family history of AMD
(d) Signs of late AMD
7. What percentage of practices reported some improvement 
in at least one of their AMD patients following 
supplementation?
(a) 20%
(b) 22%
(c) 24%
(d) 26%
8. Which one of the following supplements showed the 
highest improvement in AMD?
(a) Macushield
(b) ICaps
(c) Ocuvite Lutein
(d) Ocuvite Preservision
9. What percentage of patients currently have the capacity to 
measure macular pigment in people at risk of AMD?
(a) 3.2%
(b) 3.7%
(c) 4.2%
(d) 4.7%
10. Regarding measuring macular pigment, which of the 
following statements is incorrect?
(a) Heterochromic flicker photometry (HFP) is the gold 
standard
(b) The Macuscope allows customisation of the method
(c) The M-POD can yield lower results compared to the 
gold standard
(d) The clinical densitometer produces reliable and 
reproducible results
Online AMD research study for optometrists: current practice in the Republic of Ireland and UK
143
11. Regarding eye supplements, which of the following 
statements is incorrect?
(a) ICaps and Macushield were the two most commonly 
recommended supplements
(b) Ocuvite Lutein has many supporting published studies
(c) Macushield has a growing body of evidence in support of 
this supplement
(d) ICaps has many supporting published studies
12. Which combination of macular carotenoids is most 
appropriate for patients at risk of, or presenting with, AMD?
(a) Lutein and zeaxanthin
(b) Lutein alone
(c) Lutein and meso-zeaxanthin
(d) Lutein, zeaxanthin and meso-zeaxanthin
 Reflection
1.  What impact has your learning had, or might it have, on:
	 •			your	 patients	 or	 other	 service	 users	 (eg	 those	 who	 refer	
patients to you, members of staff whom you supervise)?
	 •		yourself	(improved	knowledge,	performance,	confidence)?	
	 •		your	colleagues?
2. How might you assess/measure this impact?
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 CPD Exercise
Now update your CPD record with this article. If you have 
completed the CET questions, the details for this article 
can be downloaded from CETOptics (at the end of the 
month). If you have not completed the CET questions 
you can cut and paste the relevant details (title/learning 
outcomes etc.) from the pdf copy of the article which is 
posted on the College website.
Once you have downloaded the details of the article, 
answer the reflective questions to complete the CPD 
activity.
If you wish, you can type your reflections into the box 
below and then copy them into your online record.
